King Luther Capital Management Corp Increases Stock Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

King Luther Capital Management Corp increased its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 19.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 20,540 shares of the company’s stock after acquiring an additional 3,324 shares during the quarter. King Luther Capital Management Corp’s holdings in Medpace were worth $6,824,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. R Squared Ltd purchased a new position in shares of Medpace in the 4th quarter valued at approximately $30,000. SBI Securities Co. Ltd. acquired a new stake in shares of Medpace during the fourth quarter worth $31,000. Stone House Investment Management LLC purchased a new position in Medpace in the 3rd quarter valued at $33,000. Ashton Thomas Securities LLC acquired a new position in Medpace in the 3rd quarter valued at $37,000. Finally, Jones Financial Companies Lllp raised its position in Medpace by 2,750.0% during the 4th quarter. Jones Financial Companies Lllp now owns 114 shares of the company’s stock worth $38,000 after buying an additional 110 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Trading Down 3.4 %

Shares of Medpace stock opened at $325.87 on Wednesday. The company has a 50-day moving average of $341.06 and a two-hundred day moving average of $342.12. The stock has a market cap of $9.93 billion, a PE ratio of 25.80, a price-to-earnings-growth ratio of 3.81 and a beta of 1.47. Medpace Holdings, Inc. has a 12-month low of $302.01 and a 12-month high of $459.77.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. On average, sell-side analysts forecast that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Robert W. Baird lifted their target price on shares of Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a report on Monday, January 27th. Seven investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $381.44.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.